The estimated treatment difference was 1.44 points (80% confidence interval [CI]: 2.84, 0.05) (Table 1)
The P-scores, which rank treatments based on their likelihood of causing adverse events, were highest for FGF21 (0.5955), followed by Resmetirom (0.3532) and GLP-1 (0.0911)
Several such experiments are summarized in % of pre-drug value (Fig
PubMed Randomized trialNAD+ and precursor evidence2021 Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women Human NMN source for metabolic claims while keeping population limits clear
Transforming Lives, One Step at a Time Keep reading What to Eat While on a GLP-1 When a GLP-1 medication like semaglutide or tirzepatide curbs your appetite, the challenge shifts from eating less to eating well
FAERS, FDA Adverse Event Reporting System